author-photo

Richard Anthony Brigandi

GlaxoSmithKline

12

Papers

239

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

A population analysis of the DGAT1 inhibitor GSK3008356 and its effect on endogenous and meal-induced triglyceride turnover in healthy subjects

2019 Fundamental & Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (2)
First‐in‐Human Pharmacokinetics and Safety Study of GSK3008356, a Selective DGAT1 Inhibitor, in Healthy Volunteers

2019 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (1)
A Phase 1 Randomized, Placebo‐Controlled Trial With a Topical Inhibitor of Stearoyl‐Coenzyme A Desaturase 1 Under Occluded and Nonoccluded Conditions

2019 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (1)
A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.

2016 American Journal of Kidney Diseases
Show All
- Source
- Cite
- Save
Citations (103)
Comparison of Vestipitant With Ondansetron for the Treatment of Breakthrough Postoperative Nausea and Vomiting After Failed Prophylaxis With Ondansetron

2015 Survey of Anesthesiology
Show All
- Source
- Cite
- Save
Citations (0)
Intravenous pharmacokinetics, local tolerability, and hemolysis of an SBE7‐β‐cyclodextrin formulation of the neurokinin‐1 receptor antagonist vestipitant

2015 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (5)
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

2014 Blood
Show All
- Source
- Cite
- Save
Citations (81)
Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study

2011 Blood
Show All
- Source
- Cite
- Save
Citations (12)